FDA seeks to cut repeat work for gene therapy developers

The US Food and Drug Administration has issued draft guidance designed to help cell and gene therapy developers make greater use of existing scientific and regulatory knowledge, a move aimed at trimming redundant testing without lowering safety standards.

The guidance, once finalized, will explain how sponsors can draw on publicly available information and established platform knowledge when preparing submissions for human gene therapy products using genome editing in human somatic cells.